FDA紧急授权将羟氯喹和氯喹,用于治疗特定类型的新冠病毒COVID-19感染患者

2020-04-01 MedSci原创 MedSci原创

尽管该药物现在已被批准用于紧急用途,但该授权仅适用于某些COVID-19患者,他们必须符合特定标准才能进行治疗。

在初步数据显示出具有抗新型冠状病毒COVID-19的功效后,美国食品药品监督管理局(FDA)紧急批准了具有数十年抗疟疾历史的羟氯喹和氯喹。

紧急授权来自法国的一项小型研究结果,在该研究中,接受氯喹治疗的五分之四的COVID-19患者获得了"良好"的治疗效果。接受氯喹治疗的80例患者中有65例得到改善,平均不到5天就出院了。

羟氯喹本身是有效的,但当将其加入抗生素阿奇霉素中,发现羟氯喹可产生明显的优异反应。

特朗普已经将该药视为一种潜在的治疗方法,他暗示该药已于3月20日获准在COVID-19中使用。但是,FDA迅速对此表示谴责,强调该药物仍在临床上进行测试以确定其抗COVID-19的潜力。

尽管该药物现在已被批准用于紧急用途,但该授权仅适用于某些COVID-19患者,他们必须符合特定标准才能进行治疗。

诺华已经向美国捐赠了3000万剂羟氯喹,而德国制药公司拜耳公司则捐赠了100万剂氯喹。

原始出处:

http://www.pmlive.com/pharma_news/fda_grants_emergency_authorisation_to_chloroquine_for_covid-19_1331981

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1851026, encodeId=39ac1851026dc, content=<a href='/topic/show?id=0406580667c' target=_blank style='color:#2F92EE;'>#新冠病毒COVID-19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58066, encryptionId=0406580667c, topicName=新冠病毒COVID-19)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Mon Jun 08 04:22:37 CST 2020, time=2020-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798033, encodeId=cc691e980330b, content=<a href='/topic/show?id=26c56e923f7' target=_blank style='color:#2F92EE;'>#特定类型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67923, encryptionId=26c56e923f7, topicName=特定类型)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/F82CC4A89F97BD21D3DDB7AD5F2AD09D/100, createdBy=52952500022, createdName=ms6829001416292975, createdTime=Tue May 26 06:22:37 CST 2020, time=2020-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523285, encodeId=f4b7152328501, content=<a href='/topic/show?id=1a1de7006b0' target=_blank style='color:#2F92EE;'>#紧急#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77006, encryptionId=1a1de7006b0, topicName=紧急)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88211514540, createdName=guguangxiang, createdTime=Fri Apr 03 14:22:37 CST 2020, time=2020-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381258, encodeId=0ad938125843, content=学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Thu Apr 02 13:36:06 CST 2020, time=2020-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1027602, encodeId=7244102e60212, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Thu Apr 02 02:22:37 CST 2020, time=2020-04-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1851026, encodeId=39ac1851026dc, content=<a href='/topic/show?id=0406580667c' target=_blank style='color:#2F92EE;'>#新冠病毒COVID-19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58066, encryptionId=0406580667c, topicName=新冠病毒COVID-19)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Mon Jun 08 04:22:37 CST 2020, time=2020-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798033, encodeId=cc691e980330b, content=<a href='/topic/show?id=26c56e923f7' target=_blank style='color:#2F92EE;'>#特定类型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67923, encryptionId=26c56e923f7, topicName=特定类型)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/F82CC4A89F97BD21D3DDB7AD5F2AD09D/100, createdBy=52952500022, createdName=ms6829001416292975, createdTime=Tue May 26 06:22:37 CST 2020, time=2020-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523285, encodeId=f4b7152328501, content=<a href='/topic/show?id=1a1de7006b0' target=_blank style='color:#2F92EE;'>#紧急#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77006, encryptionId=1a1de7006b0, topicName=紧急)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88211514540, createdName=guguangxiang, createdTime=Fri Apr 03 14:22:37 CST 2020, time=2020-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381258, encodeId=0ad938125843, content=学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Thu Apr 02 13:36:06 CST 2020, time=2020-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1027602, encodeId=7244102e60212, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Thu Apr 02 02:22:37 CST 2020, time=2020-04-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1851026, encodeId=39ac1851026dc, content=<a href='/topic/show?id=0406580667c' target=_blank style='color:#2F92EE;'>#新冠病毒COVID-19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58066, encryptionId=0406580667c, topicName=新冠病毒COVID-19)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Mon Jun 08 04:22:37 CST 2020, time=2020-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798033, encodeId=cc691e980330b, content=<a href='/topic/show?id=26c56e923f7' target=_blank style='color:#2F92EE;'>#特定类型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67923, encryptionId=26c56e923f7, topicName=特定类型)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/F82CC4A89F97BD21D3DDB7AD5F2AD09D/100, createdBy=52952500022, createdName=ms6829001416292975, createdTime=Tue May 26 06:22:37 CST 2020, time=2020-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523285, encodeId=f4b7152328501, content=<a href='/topic/show?id=1a1de7006b0' target=_blank style='color:#2F92EE;'>#紧急#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77006, encryptionId=1a1de7006b0, topicName=紧急)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88211514540, createdName=guguangxiang, createdTime=Fri Apr 03 14:22:37 CST 2020, time=2020-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381258, encodeId=0ad938125843, content=学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Thu Apr 02 13:36:06 CST 2020, time=2020-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1027602, encodeId=7244102e60212, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Thu Apr 02 02:22:37 CST 2020, time=2020-04-02, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1851026, encodeId=39ac1851026dc, content=<a href='/topic/show?id=0406580667c' target=_blank style='color:#2F92EE;'>#新冠病毒COVID-19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58066, encryptionId=0406580667c, topicName=新冠病毒COVID-19)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Mon Jun 08 04:22:37 CST 2020, time=2020-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798033, encodeId=cc691e980330b, content=<a href='/topic/show?id=26c56e923f7' target=_blank style='color:#2F92EE;'>#特定类型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67923, encryptionId=26c56e923f7, topicName=特定类型)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/F82CC4A89F97BD21D3DDB7AD5F2AD09D/100, createdBy=52952500022, createdName=ms6829001416292975, createdTime=Tue May 26 06:22:37 CST 2020, time=2020-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523285, encodeId=f4b7152328501, content=<a href='/topic/show?id=1a1de7006b0' target=_blank style='color:#2F92EE;'>#紧急#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77006, encryptionId=1a1de7006b0, topicName=紧急)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88211514540, createdName=guguangxiang, createdTime=Fri Apr 03 14:22:37 CST 2020, time=2020-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381258, encodeId=0ad938125843, content=学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Thu Apr 02 13:36:06 CST 2020, time=2020-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1027602, encodeId=7244102e60212, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Thu Apr 02 02:22:37 CST 2020, time=2020-04-02, status=1, ipAttribution=)]
    2020-04-02 njwbhuang

    学习了。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1851026, encodeId=39ac1851026dc, content=<a href='/topic/show?id=0406580667c' target=_blank style='color:#2F92EE;'>#新冠病毒COVID-19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58066, encryptionId=0406580667c, topicName=新冠病毒COVID-19)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Mon Jun 08 04:22:37 CST 2020, time=2020-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798033, encodeId=cc691e980330b, content=<a href='/topic/show?id=26c56e923f7' target=_blank style='color:#2F92EE;'>#特定类型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67923, encryptionId=26c56e923f7, topicName=特定类型)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/F82CC4A89F97BD21D3DDB7AD5F2AD09D/100, createdBy=52952500022, createdName=ms6829001416292975, createdTime=Tue May 26 06:22:37 CST 2020, time=2020-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523285, encodeId=f4b7152328501, content=<a href='/topic/show?id=1a1de7006b0' target=_blank style='color:#2F92EE;'>#紧急#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77006, encryptionId=1a1de7006b0, topicName=紧急)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88211514540, createdName=guguangxiang, createdTime=Fri Apr 03 14:22:37 CST 2020, time=2020-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381258, encodeId=0ad938125843, content=学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Thu Apr 02 13:36:06 CST 2020, time=2020-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1027602, encodeId=7244102e60212, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Thu Apr 02 02:22:37 CST 2020, time=2020-04-02, status=1, ipAttribution=)]
    2020-04-02 公卫新人

    新冠肺炎,疫情何时才能消失

    0

相关资讯

FDA批准Actemra(tocilizumab)治疗重症COVID-19肺炎的III期临床试验

罗氏公司旗下的Genentech本周一宣布,FDA已批准了一项III期临床试验(COVACTA研究)。

君实生物特瑞普利单抗联合阿昔替尼治疗黏膜黑色素瘤获得美国FDA孤儿药资格认定

3月27日,君实生物宣布,由公司自主研发的抗PD-1单抗特瑞普利单抗(商品名:拓益,产品代号:JS001)联合阿昔替尼治疗黏膜黑色素瘤于近日获得美国食品药品监督管理局(FDA)孤儿药资格认定。

新冠疫情下临床试验指南--FDA, EMA和NMPA之比较

新冠疫情流行期间,FDA(美国食药品监督局)和EMA (欧洲药品管理局)分别于3月18号和3月20日各自发布了“在COVID-19大流行期间的临床试验应对指南”

5分钟!FDA紧急使用授权批准雅培COVID-19即时检测!

今天雅培宣布,美国FDA授予了其检测新型冠状病毒(COVID-19)的分子即时检测(point-of-care test, POCT)紧急使用授权(Emergency Use Authori

FDA批准S1P受体调控剂ozanimod用于多发性硬化症药物

今天FDA批准了施贵宝的多发性硬化症药物、S1P受体调控剂ozanimod(商品名ZEPOSIA),用于成人复发性MS(RRMS)患者的治疗。

FDA继续加快COVID-19新疗法的开发

美国食品和药品监督管理局(FDA)提出了一项新计划--冠状病毒治疗加速计划(CTAP),FDA正在使用该机构可使用的所有工具,以尽快为COVID-19患者提供新疗法。